Skip to content

Atogepant

Calcitonin Gene-related Peptide Receptor Antagonist — NERVOUS SYSTEM

Also known as: AGN-241689, MK-8031, qulipta

OnpEMA approvedFDA approvedATC N02CD07

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Atogepant is an onp drug in the Calcitonin Gene-related Peptide Receptor Antagonist class catalogued in DrugCentral. It was first approved by the FDA in 2021. Its mechanism of action is classified as Calcitonin Gene-related Peptide Receptor Antagonists. DrugCentral lists 1 molecular target, including CALCRL. Recorded indications include Preventive treatment of episodic migraine in adults.

  • Approval status: onp (first approved 2021 by the FDA).
  • Drug class: Calcitonin Gene-related Peptide Receptor Antagonist.
  • Mechanism of action: Calcitonin Gene-related Peptide Receptor Antagonists.
  • Molecular targets: CALCRL (1 listed in DrugCentral).
  • Indications: Preventive treatment of episodic migraine in adults.
  • ATC code: N02CD07 (Calcitonin gene-related peptide (CGRP) antagonists).
  • Molecular formula: C29H23F6N5O3; molecular weight 603.52 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Preventive treatment of episodic migraine in adults

Mechanism & targets

Mechanism of action (MoA)Calcitonin Gene-related Peptide Receptor Antagonists
Established pharmacologic classCalcitonin Gene-related Peptide Receptor Antagonist

Molecular targets (1)

TargetGeneActionActivity
Calcitonin gene-related peptide type 1 receptorCALCRLantagonistKi 10.82

Regulatory approvals (2)

DateAgencyMarketed asApplicantOrphan
2023-08-11EMA—AbbVie Deutschland GmbH & Co. KG
2021-09-28FDA—ABBVIE INC

ATC classification

ATC codeTherapeutic hierarchy
N02CD07NERVOUS SYSTEM › ANALGESICS › ANTIMIGRAINE PREPARATIONS › Calcitonin gene-related peptide (CGRP) antagonists

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Constipation212.5
Nausea121.8
Migraine80.7
Drug ineffective47.2
Headache39.0
Weight decreased37.8
Therapeutic response shortened36.9
Dizziness32.6
Product administration interrupted29.5
Therapy interrupted29.4
Intentional dose omission29.3
Surgery29.3

Chemical structure

Molecular formulaC29H23F6N5O3
Molecular weight603.52 g/mol
CAS number1374248-81-3
InChIKeyQIVUCLWGARAQIO-OLIXTKCUSA-N
PubChem CID72163100
C[C@@H]1[C@@H](C[C@@H](C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(C[C@@]4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=C(C=CC(=C6F)F)F

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Atogepant used for?

DrugCentral lists the following indications for Atogepant: Preventive treatment of episodic migraine in adults.

How does Atogepant work?

Atogepant is classified as Calcitonin Gene-related Peptide Receptor Antagonists; its molecular targets in DrugCentral include CALCRL (antagonist).

When was Atogepant first approved?

Atogepant was first approved by the FDA in 2021.

What drug class does Atogepant belong to?

Atogepant is in the Calcitonin Gene-related Peptide Receptor Antagonist class.

What is the chemical formula of Atogepant?

Atogepant has the molecular formula C29H23F6N5O3 and a molecular weight of 603.52 g/mol.

Browse: all drugs starting with A · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusONP
First approval2021-09-28
AgencyFDA
Targets1
Indications1
FormulaC29H23F6N5O3
DrugCentral ID5472
Interactive profile